India, June 5 -- InnoCare Pharma Limited (INCPF), a biopharmaceutical company, on Friday announced promising Phase 2b results for Orelabrutinib in treating systemic lupus erythematosus (SLE). The data was presented at the 2026 Congress of the European Alliance of Associations for Rheumatology (EULAR).
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that effects the skin, joints, kidneys, and associated organ systems in affected individuals. The disease is often treated with corticosteroids, which can cause significant cumulative toxicity.
Orelabrutinib is a novel (Bruton-Kinase) BTK- inhibitor that was developed as an immunotherapy for cancers and autoimmune diseases.
The randomized, double-blind, placebo-controlled Ph...